Rheumatoid arthritis (RA) is associated with high frequency of comorbidities and increased risk of polypharmacy. Although there is a great potential for complications, there is a gap in literature on polypharmacy in patients with rheumatic arthritis.
Objective:
To evaluate the prevalence and factors associated with polypharmacy in a population in a real-life setting.
Methods:
A cross-sectional multicenter study was conducted in Brazil. Patients underwent clinical evaluation and medical records analysis. Polypharmacy was considered as a dependent variable. To test independent variables, we used Poisson regression.
Results:
We evaluated 792 patients (89% female, median age 56.6 years). Median duration of disease was 12.7 years, 78.73% had a positive rheumatoid factor. The median of disease activity score-28 was 3.5 (disease with mild activity), median of the clinical disease activity index score was 9, and median of health assessment questionnaire-disability index was 0.875; 47% used corticosteroids, 9.1% used nonsteroidal anti-inflammatory drugs, 90.9% used synthetic disease-modifying antirheumatic drugs, 35.7% used biologic disease-modifying antirheumatic drugs (DMARDs). In total, 537 (67.9%) patients used 5 or more drugs. Polypharmacy showed a relationship with a number of comorbidities and use of specific drugs (corticosteroids, methotrexate, and biological DMARDs).
Conclusion:
We found a high prevalence of polypharmacy (67.9%) in RA. Solutions to management this problem should be stimulated.
MasnoonNShakibSKalisch-EllettL, et al.What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17(1):230. DOI: 10.1186/s12877-017-0621-
2.
Le ResteJYNabbePLazicD, et al.How do general practitioners recognize thedefinitionofmultimorbidity? A European qualitative study. Eur J Gen Pract. 2016; 22(3):159–168.
NellVPMacholdKPEberlG, et al.Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheu- matoid arthritis. Rheumatology (Oxford). 2004; 43(7):906–914.
6.
SmolenJSAletahaDBijlsmaJW, et al.Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69(4):631–637.
7.
SmolenJSLandeweRBijlsmaJ, et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6):960–977.
8.
SinghJASaagKGBridgesSLJr, et al.2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016; 68(1):1–26.
9.
MotaLMHDKakehasiAMGomidesAPM, et al.2017Recommendationsof theBraziliansociety of rheumatology for the pharmacological treatment of rheumatoid arthritis. Adv Rheumatol. 2018;58(1):2.
10.
DougadosM. Comorbidities in rheumatoid arthritis. Curr Opin Rheumatol. 2016; 28(3):282–288.
11.
TuressonC. Comorbidity in rheumatoid arthritis. Swiss Med Wkly. 2016;146:w14290.
12.
van OnnaMBoonenA. The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskelet Disord. 2016; 17:184.
13.
KimJParishAL. Polypharmacy and medication management in older adults. Nurs Clin North Am. 2017; 52(3):457–468.
14.
SiroisCLarocheMLGuénetteL, et al.Polypharmacyin multimorbid older adults: protocol for a systematic review. Syst Rev. 2017;6(1):104.
15.
SharmaMLohKPNightingaleG, et al.Polypharmacyand potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016; 7(5):346–353.
16.
PereiraKGPeresMAIopD, et al.Polypharmacy among the elderly: a population-based study. Rev Bras Epidemiol. 2017; 20(2):335–344.
17.
PatelPJHaywardKLRudraR, et al.Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management. Medicine (Baltimore). 2017; 96(26):e6761.
18.
AbolbashariMMacaulayTEWhayneTF, et al.Polypharmacyin cardiovascular medicine: problems and promises!Cardiovasc Hematol Agents Med Chem. 2017;15(1):31–39.
19.
Castelar-PinheiroGRVargas-SantosABde AlbuquerqueCP, et al.The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil. Adv Rheuml. 2018;58(1):9. DOI: 10.1186/s42358-018-0017-9
20.
ArnettFCEdworthySMBlochDA, et al.The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–324.
21.
AletahaDNeogiTSilmanAJ, et al.2010 Rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581.
22.
van der HeijdeDMvan’t HofMAvan RielPL, et al.Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis. 1992; 51(2):177–181.
23.
AletahaDSmolenJ. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(Suppl 39):S100–108.
24.
van GroenMMten KloosterPMTaalE, et al.Application of the health assessment questionnaire disability index to various rheumatic diseases. Qual Life Res.2010;19(9):1255–1263.
25.
BarrosAJHirakataVN:. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21.
26.
HosmerDWLemeshowS. Applied Logistic Regression. New York, NY: John Wiley & Sons;1989.
27.
AllisonPD. Logistic Regression Using SAS-Theory and Application. Cary, NC: SAS Institute; 1999.
28.
QatoDMWilderJSchummLP, et al.Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176(4):473–482.
29.
WastessonJWCedazo MinguezAFastbomJ, et al.The composition of polypharmacy: a register-based study of Swedes aged 75 years and older. PLoS One. 2018;13(3):e0194892. https://doi.org/10.1371/journal.pone.0194892.
30.
NascimentoRCRMÁlvaresJGuerra JuniorAA, et al.Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System [in Portuguese]. Rev Saude Publica. 2017;51(Suppl 2):10s.
31.
GomesMSAmorimWWMoraisRS, et al.Polypharmacyin older patients at primary care units in Brazil. Int J Clin Pharm. 2019. doi:10.1007/s11096-018-00780-5.
32.
RossiMIYoungAMaherR, et al.Polypharmacy and health beliefs in older outpatients. Am J Geriatr Pharmacother. 2007;5(4):317–323.
33.
HajjarEHanlonJTSloaneRJ, et al.Unnecessary drug use in frail older people at hospital discharge.J Am Geriatr Soc. 2005;53(9):1518–1523.
34.
NobiliALicataGSalernoF, et al.Polypharmacy, length of hospital stay and inpatient mortality among elderly patients in internal medicine wards. Eur J Clin Pharmacol. 2011;67(5):507–519.
35.
DwyerLLHanBWoodwellDA, et al.Polypharmacy in nursing home residents in the United States: results of the 2004 national nursing home survey.Am J Geriatr Pharmacother. 2009;8(1):63–72.
36.
BronskillSEGillSSPatersonJM, et al.Exploring variation in rates of polypharmacy across long term care homes. JAMDA. 2012;13(3):309.e15-e21
37.
MaherRLHanlonJHajjarER. Clinical consequences of polypharmacyin elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
38.
NawrotJBoonenAPeetersR, et al.Rheumatologists’views and experiences in managing rheumatoid arthritis in elderly patients: aqualitative study. J Rheumatol. 2018;45(5):590–594.
39.
KievitWvan HulstLvan RielP, et al.Factors that influence rheumatologists’ decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis. Arthritis Care Res. 2010;62(6):842–847.
40.
FraenkelL.RabidouNDharR. Are rheumatologists’ treatment decisions influenced by patients’ age?Rheumatology. 2006;45(12): 1555–1557.
41.
FrahmNHeckerMZettlUK. Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: a single-center study. PLoS One. 2019;14(1):e0211120. https://doi.org/10.1371/journal.pone.0211120.
42.
TreharneGJDouglasKMIwaszkoJ, et al.Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. MusculoskeletalCare.2007;5(4):175–190.
43.
FilkovaMCarvalhoJNortonS, et al.Polypharmacy and unplanned hospitalizations in patients with rheumatoid arthritis. J Rheumatol. 2017; 44(12):1786–1793.
44.
WastessonJ WMorinLTanECK, et al.An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185–1196.
45.
González-GamboaLMBarocio-RamírezAKRocha-MuñozAD, et al.Disease activity score on 28 Joints and polypharmacy are independent predictors for health related quality of life evaluated by INCAVISA in patients with rheumatoid arthritis. J Clin Rheumatol. 2016;22(8):399–404.
46.
RoodenrijsNMTde HairMJHvan der GoesMC, et al.Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis.2018;77(12):1705–1709.
47.
MolokhiaMMajeedA. Current and future perspectives on the management of polypharmacy. BMC Fam Pract.2017;18(1):70.
48.
Machado-AlbaJEGaviria-MendozaAMachado-DuqueME, et al.Deprescribing: a new goal focusedonthe patient. Expert Opin Drug Saf.2017;16(2):111–112.
49.
StewartDMairAWilsonM, et al.Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments. Expert Opin Drug Saf. 2017;16(2):203–213.
